<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007406</url>
  </required_header>
  <id_info>
    <org_study_id>DP13C201</org_study_id>
    <nct_id>NCT04007406</nct_id>
  </id_info>
  <brief_title>DP13 - A Phase II Study in Patients With Primary Aldosteronism</brief_title>
  <official_title>DP13 - A Phase II Study in Patients With Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of DP13, Over an 8-week Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damian Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damian Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present phase II study is to determine whether DP13 displays the clinical
      safety and efficacy profile to support further development in patients with primary
      aldosteronism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II, multi-centre, randomized, parallel group, baseline-and withdrawal-controlled
      study in 36 patients with primary aldosteronism to determine the dose-dependent efficacy,
      safety and tolerability of DP13 after a 2-week single-blind placebo run-in period followed by
      a randomized 8-week double-blind treatment period. After an additional single-blind, 2-week
      DP13 placebo withdrawal period, patients are switched to standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in aldosterone</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in aldosterone from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ambulatory blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in ambulatory blood pressure from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurrence of treatment-emergent adverse events and serious adverse events over entire study duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in blood pressure from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in potassium from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in electrolytes</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in sodium from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in electrolytes</description>
  </other_outcome>
  <other_outcome>
    <measure>Steady state pharmacokinetics</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in DP13 concentrations</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>DP13 low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP13 middle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP13 high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP13 for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP13</intervention_name>
    <description>DP13 systemic administration</description>
    <arm_group_label>DP13 high</arm_group_label>
    <arm_group_label>DP13 low</arm_group_label>
    <arm_group_label>DP13 middle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with a guideline-recommended diagnosis of primary aldosteronism

        Exclusion Criteria:

        Patients with primary aldosteronism and

          -  hyperkalemia

          -  prolonged QT intervals

          -  refusal of special contraception measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paolo Mulatero, Prof</last_name>
    <phone>0116336920</phone>
    <email>paolo.mulatero@unito.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans-Rudolf Brunner, Prof.</last_name>
    <phone>0616412510</phone>
    <email>hrbrunner13@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Mulatero, Prof.</last_name>
      <phone>0116336920</phone>
      <email>paolo.mulatero@unito.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

